Fig. 4: TICs, TME scores, and PI3K-Akt signaling pathway were associated with the survival and clinicopathological characteristics of TNBC patients.

A The top 20 DEGs in five different types of breast cancer and normal breast tissue samples (GSE65194), ****P-value < 0.0001. [TNBC (n = 55), Her2 (n = 39), Luminal B (n = 30), Luminal A (n = 29), Healthy (n = 11)]. B The barplot showing the different proportions of 22 TICs in different types of breast cancer samples (n = 103). C The correlations between 22 different kinds of TICs. The value in each small box represents the P value of correlation between the two kinds of TICs. The chroma of each small color box represents the corresponding correlation value between the two kinds of TICs. Pearson coefficient is used for the significance test. D The violin plot showed the significantly differentially expression of immune cells between TNBC (n = 55) and non-TNBC (n = 48) samples. E, F Kaplan–Meier survival analysis depending on overall survival (OS) (E) or metastases-free survival (MFS) (F) was performed for breast cancer patients with high or low ESTIMATEScore, StromalScore, and ImmuneScore, respectively. G–I Distribution of ESTIMATEScore, StromalScore, and ImmuneScore in histological type (G), PR (H), Her2 (I). J, K The heatmap (J) and volcano (K) for 3378 DEGs. The patients were grouped according to their high and low ImmuneScore. L, M The heatmap (L) and volcano (M) for 3378 DEGs. The patients were grouped according to their high and low StromalScore. The DEGs were calculated by Wilcoxon rank sum test. The results with the criterion of logFC > 0.8, P < 0.01, and false discovery rate (FDR) < 0.01 as the significance threshold. N–O The venn diagram showed 1153 upregulated DEGs (N) and 2591 downregulated DEGs (O) both in data regarding ImmuneScore or StromalScore. P–Q GO and KEGG enrichment analysis for 3744 DEGs displayed the enrichment of immune-related GO terms (P) and signaling pathways (Q), with p and q value < 0.05 as the significance threshold. R The heatmap showed that the 77 genes enriched in the PI3K-Akt signaling pathway have different expression levels in different subtypes of BCa, ****p < 0.0001. S The Venn diagram showed the 23 target genes through the cross-analysis of genes from PI3K-Akt signaling pathway and target genes of miR-637. T, U The expression levels of Akt1 (T) and CCND1 (cyclinD1) (U) between different types of breast cancer.